Walleye Trading LLC Arcus Biosciences, Inc. Transaction History

Walleye Trading LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$13.43 - $19.63 $33,588 - $49,094	-2,501 Reduced 7.2%	32,251 $615,000
Q3 2023 Nov 14, 2023	SELL	$17.62 - $23.54 $730,525 - $975,968	-41,460 Reduced 54.4%	34,752 $623,000
Q2 2023 Aug 14, 2023	BUY	$16.97 - $22.03 $652,666 - $847,273	38,460 Added 101.88%	76,212 $1.55 Million
Q1 2023 May 15, 2023	BUY	$15.96 - $23.15 $602,521 - $873,958	37,752 New	37,752 $688,000
Q3 2021 Nov 15, 2021	SELL	$26.93 - $37.68 $901,589 - $1.26 Million	-33,479 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$22.75 - $35.77 $761,647 - $1.2 Million	33,479 New	33,479 $919,000

200

51.5M

236K

141K

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $1.02B
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

Get notified when there are updates to the investment portfolio of Walleye Trading LLC, based on Form 13F filings with the SEC.

Stay updated on Walleye Trading LLC with notifications on news.